📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Agios

1.1 - Company Overview

Agios Logo

Agios

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of biopharmaceutical therapeutics focused on cancer metabolism, offering PYRUKYND (mitapivat), an approved therapy for adults with pyruvate kinase deficiency to treat hemolytic anemia; late-stage trials of mitapivat for thalassemia and sickle cell disease; AG-946, an early-stage PK activator; and patient access services including myAgios and a Global Managed Access Program.

Products and services

  • PYRUKYND (mitapivat): Approved therapy for adults with pyruvate kinase (PK) deficiency that treats hemolytic anemia with an indication specifically for adult patients
  • Clinical Trials for Sickle Cell Disease: Late-stage clinical trials evaluating mitapivat for the treatment of sickle cell disease, measuring therapeutic performance in this hematologic condition
  • Clinical Trials for Thalassemia: Late-stage clinical trials evaluating mitapivat for the treatment of thalassemia, assessing therapeutic activity and clinical outcomes in this anemia

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Agios

Immune-Onc Therapeutics Logo

Immune-Onc Therapeutics

HQ: United States Website
  • Description: Provider of therapeutic antibodies for cancer treatment, developing IO-202, a humanized IgG1 targeting LILRB4 to deplete LILRB4-expressing cells in blood cancers, autoimmune, and inflammatory diseases; IO-108, a fully human IgG4 targeting LILRB2 to block cancer-associated immune suppression in solid tumors; and IO-312, a bispecific targeting LILRB4 and CD3 for AML and other hematologic malignancies.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Immune-Onc Therapeutics company profile →
Galil Medical Logo

Galil Medical

HQ: United States Website
  • Description: Provider of minimally invasive cryotherapy technology and systems for various clinical applications, using compressed Argon gas to freeze and ablate diseased tissue in procedures referred to as cryotherapy, cryoablation, or cryosurgery.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Galil Medical company profile →
CASI Pharmaceuticals Logo

CASI Pharmaceuticals

HQ: United States Website
  • Description: Provider of business development aimed at building a pipeline through mutually beneficial transactions.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full CASI Pharmaceuticals company profile →
Pheon Therapeutics Logo

Pheon Therapeutics

HQ: United Kingdom Website
  • Description: Provider of antibody-drug conjugate (ADC) programs for difficult-to-treat cancers. Offerings include PHN-010, an ADC targeting a transmembrane protein over-expressed in multiple solid tumors with low expression in healthy tissues; development of first-in-class solid tumor programs with in vivo proof of concept; and proprietary payloads to overcome resistance, featuring novel modes of action and tunable potency.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Pheon Therapeutics company profile →
Mirna Therapeutics Logo

Mirna Therapeutics

HQ: United States Website
  • Description: Provider of microRNA-directed oncology therapies as a biopharmaceutical company.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Mirna Therapeutics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Agios

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Agios

2.2 - Growth funds investing in similar companies to Agios

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Agios

4.2 - Public trading comparable groups for Agios

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Agios

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Agios

What does Agios do?

Agios is a provider of biopharmaceutical therapeutics focused on cancer metabolism, offering PYRUKYND (mitapivat), an approved therapy for adults with pyruvate kinase deficiency to treat hemolytic anemia; late-stage trials of mitapivat for thalassemia and sickle cell disease; AG-946, an early-stage PK activator; and patient access services including myAgios and a Global Managed Access Program.

Who are Agios's competitors?

Agios's competitors and similar companies include Immune-Onc Therapeutics, Galil Medical, CASI Pharmaceuticals, Pheon Therapeutics, and Mirna Therapeutics.

Where is Agios headquartered?

Agios is headquartered in United States.

How many employees does Agios have?

Agios has 1,000 employees 🔒.

When was Agios founded?

Agios was founded in 2010 🔒.

What sector and industry vertical is Agios in?

Agios is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Agios

Who are the top strategic acquirers in Agios's sector and industry

Top strategic M&A buyers and acquirers in Agios's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Agios?

Top strategic M&A buyers groups and sectors for Agios include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Agios's sector and industry vertical

Which are the top PE firms investing in Agios's sector and industry vertical?

Top PE firms investing in Agios's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Agios's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Agios's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Agios's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Agios include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Agios's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Agios?

The key public trading comparables and valuation benchmarks for Agios include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Agios for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Agios with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Agios's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Agios with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Agios's' sector and industry vertical?

Access recent funding rounds and capital raises in Agios's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Agios